Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes : an individual patient data meta-analysis of 9,153 patients
dc.contributor.author | Ahuja, Shama D. | en_ZA |
dc.contributor.author | Ashkin, David | en_ZA |
dc.contributor.author | Avendano, Monika | en_ZA |
dc.contributor.author | Banerjee, Rita | en_ZA |
dc.contributor.author | Bauer, Melissa | en_ZA |
dc.contributor.author | Bayona, Jamie N. | en_ZA |
dc.contributor.author | Becerra, Mercedes C. | en_ZA |
dc.contributor.author | Benedetti, Andrea | en_ZA |
dc.contributor.author | Burgos, Marcos | en_ZA |
dc.contributor.author | Centis, Rosella | en_ZA |
dc.contributor.author | Chan, Eward D. | en_ZA |
dc.contributor.author | Chiang, Chen-Yuan | en_ZA |
dc.contributor.author | Cox, Helen | en_ZA |
dc.contributor.author | D'Ambrosio, Lia | en_ZA |
dc.contributor.author | DeRiemer, Kathy | en_ZA |
dc.contributor.author | Dung, Nguyen Huy | en_ZA |
dc.contributor.author | Enarson, Donald | en_ZA |
dc.contributor.author | Falzon, Dennis | en_ZA |
dc.contributor.author | Flanagan, Katherine | en_ZA |
dc.contributor.author | Flood, Jennifer | en_ZA |
dc.contributor.author | Garcia-Garcia, Maria L. | en_ZA |
dc.contributor.author | Ghandi, Neel | en_ZA |
dc.contributor.author | Granich, Reuben M. | en_ZA |
dc.contributor.author | Hollm-Delgado, Maria G. | en_ZA |
dc.contributor.author | Holtz, Timothy H. | en_ZA |
dc.contributor.author | Iseman, Michael D. | en_ZA |
dc.contributor.author | Jarlsberg, Leah G. | en_ZA |
dc.contributor.author | Keshavjee, Salmaan | en_ZA |
dc.contributor.author | Kim, Hye-Ryoun | en_ZA |
dc.contributor.author | Koh, Won-Jung | en_ZA |
dc.contributor.author | Lancaster, Joey | en_ZA |
dc.contributor.author | Lange,Christophe | en_ZA |
dc.contributor.author | Lange, Wiel C. M. de | en_ZA |
dc.contributor.author | Leimane, Vaira | en_ZA |
dc.contributor.author | Leung, Chi Chiu | en_ZA |
dc.contributor.author | Li, Jiehui | en_ZA |
dc.contributor.author | Menzies, Dick | en_ZA |
dc.contributor.author | Migliori, Giovanni B. | en_ZA |
dc.contributor.author | Mishustin, Sergey P. | en_ZA |
dc.contributor.author | Mitnick, Carole D. | en_ZA |
dc.contributor.author | Narita, Masa | en_ZA |
dc.contributor.author | O'Riordan, Philly | en_ZA |
dc.contributor.author | Pai, Madhukar | en_ZA |
dc.contributor.author | Palmero, Domingo | en_ZA |
dc.contributor.author | Park, Seung-kyu | en_ZA |
dc.contributor.author | Pasvol, Geoffrey | en_ZA |
dc.contributor.author | Pena, Jose | en_ZA |
dc.contributor.author | Perez-Guzman, Carlos | en_ZA |
dc.contributor.author | Quelapio, Maria I. D. | en_ZA |
dc.contributor.author | Ponce-De-Leon, Alfredo | en_ZA |
dc.contributor.author | Riekstina, Vija | en_ZA |
dc.contributor.author | Robert, Jerome | en_ZA |
dc.contributor.author | Royce, Sarah | en_ZA |
dc.contributor.author | Schaaf, H. Simon | en_ZA |
dc.contributor.author | Seung, Kwonjune J. | en_ZA |
dc.contributor.author | Shah, Lena | en_ZA |
dc.contributor.author | Shim, Tae Sun | en_ZA |
dc.contributor.author | Shin, Sonya S. | en_ZA |
dc.contributor.author | Shiraishi, Yuji | en_ZA |
dc.contributor.author | Sifuentes-Osornio, Jose | en_ZA |
dc.contributor.author | Sotgiu, Giovanni | en_ZA |
dc.contributor.author | Strand, Matthew J. | en_ZA |
dc.contributor.author | Tabarsi, Payam | en_ZA |
dc.contributor.author | Tupasi, Thelma E. | en_ZA |
dc.contributor.author | Altena, Robert van | en_ZA |
dc.contributor.author | Van der Walt, Martie | en_ZA |
dc.contributor.author | Werf, Tjip S. van der | en_ZA |
dc.contributor.author | Vargas, Mario H. | en_ZA |
dc.contributor.author | Viiklepp, Pirett | en_ZA |
dc.contributor.author | Westenhouse, Janice | en_ZA |
dc.contributor.author | Yew, Wing Wai | en_ZA |
dc.contributor.author | Yim, Jae-Joon | en_ZA |
dc.date.accessioned | 2013-02-08T10:12:48Z | |
dc.date.available | 2013-02-08T10:12:48Z | |
dc.date.issued | 2012-08-28 | |
dc.description | CITATION: Ahuja, S. D., et al. 2012. Mutlidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes : an individual patient data meta-analysis of 9,153 patients. PLoS Medicine, 9(8): 1-16, doi: 10.1371/journal.pmed.1001300. | |
dc.description | The original publication is available at http://journals.plos.org/plosmedicine | |
dc.description.abstract | Background: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB. Methods and Findings: Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1–6.0]), ofloxacin (aOR: 2.5 [1.6–3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3–2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3–3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7–4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7–4.3]), ofloxacin (aOR: 2.3 [1.3–3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4–2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9–3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4–6.0]). Conclusions: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment. | en_ZA |
dc.description.version | Publisher's version | en_ZA |
dc.format.extent | 16 pages ; illustrations | |
dc.identifier.citation | Ahuja, S. D., et al. 2012. Mutlidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes : an individual patient data meta-analysis of 9,153 patients. PLoS Medicine, 9(8): 1-16, doi: 10.1371/journal.pmed.1001300 | en_ZA |
dc.identifier.issn | 1549-1676 (online) | |
dc.identifier.issn | 1549-1277 (print) | |
dc.identifier.other | doi: 10.1371/journal.pmed.1001300 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/79325 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | Public Library of Science | en_ZA |
dc.rights.holder | Authors retain copyright | en_ZA |
dc.subject | Multidrug-resistant tuberculosis -- Treatment | en_ZA |
dc.subject | Patient Outcomes | en_ZA |
dc.subject | Meta-analysis | en_ZA |
dc.title | Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes : an individual patient data meta-analysis of 9,153 patients | en_ZA |
dc.type | Article | en_ZA |